ALS TDI, Gladstone Institutes to discover potential ALS treatments
Wednesday, December 5, 2012
The ALS Therapy Development Institute (ALS TDI), aimed at developing effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS), and the Gladstone Institutes, a nonprofit biomedical-research organization, have formed a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.
“We are thrilled about the potential this collaboration holds to accelerate ALS therapeutic development,” said Steve Perrin, CEO and chief scientific officer, ALS TDI. “Both our organizations have unique infrastructures, and by linking them this way, we may be able to advance potential treatments faster than before.”
Gladstone will evaluate potential pharmaceutical compounds using a human model of ALS. Gladstone generated the model by transforming skin cells from ALS patients into stem cells, known as induced pluripotent stem cells (iPS cells), and then programming them into neurons. The technique builds on a discovery for which Shinya Yamanaka, MD, PhD, a Gladstone senior investigator, won the 2012 Nobel Prize in physiology or medicine.
This particular iPS-based ALS model includes a gene mutation that produces TDP-43, a protein commonly found in most forms of ALS. Promising drug compounds that pass the initial evaluation process at Gladstone will be fast-tracked for pre-clinical testing at ALS TDI, which will assess the compounds for activity and efficacy in various mouse models of human neurodegeneration.
“We hope our human model of ALS will help us to move quickly and effectively to identify promising therapeutic candidates for ALS,” said Steve Finkbeiner, MD, PhD, Gladstone senior investigator, and a professor of neurology and physiology at the University of California, San Francisco, with which Gladstone is affiliated. “The strong evidence that abnormal TDP-43 protein is involved in the development of ALS, coupled with models that may replicate ALS more faithfully than other tools, may speed development of therapies for the thousands of individuals diagnosed with this devastating disease.”